Is BBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BBIO. It does not provide personalized investment advice.

BBIO (BridgeBio Pharma, Inc. Common Stock) Stock Analysis - Financials

BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of August 15, 2026, BBIO trades at $80.05 with a market cap of $15.61B and a P/E ratio of -22.49. BBIO moved -1.67% today. Year to date, BBIO is +2.08%; over the trailing twelve months it is +56.04%. Its 52-week range spans $26.55 to $93.42. Analyst consensus is strong buy with an average price target of $106.15. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are BBIO's key financials?

BBIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BBIO recently traded at $80.05. Market cap is $15.61B. P/E ratio is -22.49. Revenue is $713.07M.

BBIO Key Metrics

Key financial metrics for BBIO
Metric	Value
Price	$80.05
Market Cap	$15.61B
P/E Ratio	-22.49
EPS	$-3.56
Dividend Yield	0.00%
52-Week High	$93.42
52-Week Low	$26.55
Volume	2.87M
Avg Volume	0
Revenue (TTM)	$713.07M
Net Income	$-702.02M
Gross Margin	94.44%

BBIO Analyst Consensus

14 analysts cover BBIO: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $106.15.

Common questions about BBIO

What are BBIO's key financials?: BBIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BBIO recently traded at $80.05. Market cap is $15.61B. P/E ratio is -22.49. Revenue is $713.07M.
Is BBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BBIO. It does not provide personalized investment advice.